KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th

Virtual Investor Conferences the leading proprietary investor conference series, in partnership with KCSA Strategic Communications ("KCSA"), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference to be held on April 27-28, 2022. Individual investors, institutional investors, advisors, and analysts are invited to attend this two-day virtual event showcasing live company presentations and interactive discussions focused on psychedelic treatments for mental health disorders.

"As we have seen over the past 18 months, drug development is hard. The good news is many of the companies presenting over the two-day event have shown tremendous clinical progress. I would encourage investors to take a traditional pharma or biotech view of this space and practice patience, do the proper diligence, and the rewards will be tremendous," said Lewis Goldberg, Managing Partner and Founder of KCSA's Psychedelics Practice. "Drug development for mental health care takes time, focus, and is capital intensive. The potential returns remain as dramatic as ever, it's the investors who – to steal a line from Michael Pollan – need to change their minds."

REGISTER NOW AT: https://bit.ly/3rFbSuZ

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations and schedule 1x1 meetings.

April 27 ^th Agenda:

Eastern Time (ET)	Presentation	Ticker(s)
9:30 AM	HMNC Brain Health	Private
10:00 AM	Field Trip Health Ltd.	NASDAQ: FTRP \| TSX: FTRP
10:30 AM	Psyched Wellness Ltd.	OTCQB: PSYCF \| CSE: PSYC
11:00 AM	Enveric Biosciences	NASDAQ: ENVB
11:30 AM	Lobe Sciences Ltd.	OTCQB: LOBEF \| CSE: LOBE
12:00 PM	Ninnion Therapeutics	Private
12:30 PM	PsyBio Therapeutics	OTCQB: PSYBF \| TSXV: PSYB
1:00 PM	Numinus Wellness	OTCQX: NUMIF \| TSX: NUMI

April 28 ^th Agenda:

Eastern Time (ET)	Presentation	Ticker(s)
9:30 AM	Small Pharma Inc.	OTCQB: DMTTF \| TSXV: DMT
10:00 AM	Mindset Pharma Inc.	OTCQB: MSSTF \| CSE: MSET
10:30 AM	Gilgamesh Pharma	Private
11:00 AM	Cybin Inc.	NYSE AMEX: CYBN \| NEO: CYBN
11:30 AM	Filament Health Corp.	OTCQB: FLHLF \| NEO: FH
12:00 PM	Awaken Life Sciences Corp.	OTCQB: AWKNF \| NEO: AWKN

To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com .

About Virtual Investor Conferences ^®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

About KCSA Strategic Communications

KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com .

Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

KCSA Contact:
Allison Soss / Tim Regan
KCSA Strategic Communications
conference@kcsa.com

News Provided by GlobeNewswire via QuoteMedia

tsxv:numi cannabis investing Cannabis Investing

NUMI:CA

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to share that the single-arm, open-label, compassionate access 1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC) a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials, expanding national footprint, and enhanced research
capabilities ensure Numinus' continued growth

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 ("Q1 2021"). After achieving two industry firsts, launching new compassionate access trials, and augmenting its clinical and research activity, Numinus meaningfully expanded its industry presence in Q1 2021. All financial results are reported in Canadian dollars unless otherwise stated.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Fourth Quarter and Full Year 2024 Results Conference Call on February 27, 2025

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Thursday, February 27, 2025 at 8:30 AM Eastern Time following the release of its fourth quarter and full year 2024 financial results.

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830	Passcode:	0313762
International: 1-412-542-4136	Passcode:	0313762

A live audio webcast of the conference call will be available at:
Trulieve Fourth Quarter and Full Year 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF . For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-fourth-quarter-and-full-year-2024-results-conference-call-on-february-27-2025-302368139.html

SOURCE Trulieve Cannabis Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2025/05/c7953.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Cannabis Corp. to Hold Fourth Quarter and Full Year 2024 Results Conference Call on February 27, 2025

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Thursday, February 27, 2025 at 8:30 AM Eastern Time following the release of its fourth quarter and full year 2024 financial results.

Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.

Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.

North American toll free: 1-844-824-3830	Passcode:	0313762
International: 1-412-542-4136	Passcode:	0313762

A live audio webcast of the conference call will be available at:
Trulieve Fourth Quarter and Full Year 2024 Results Call

An archived replay of the webcast will be available at:
https://investors.trulieve.com/events

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF . For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-fourth-quarter-and-full-year-2024-results-conference-call-on-february-27-2025-302368139.html

SOURCE Trulieve Cannabis Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2025/05/c7953.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

	For the three months ended November 30,
		2020		2019

Revenue	$	229,188	$	134,415
Cost of Revenue		(267,323)		(68,198)
Gross Profit		(38,135)		66,217
Expenses		(1,909,929)		(957,477)
Loss Before Other Items		(1,948,064)		(891,260)
Other items		19,327		(13,751)
Loss Before Income Taxes		(1,928,737)		(905,011)
Income tax		-		(6,240)
Loss and Comprehensive Loss for the Period	$	(1,928,737)	$	(911,251)

	For the three months ended November 30,
		2020		2019

Cash used in operating activities	$	(1,899,655)	$	(303,106)
Cash generated by (used in) investing activities		200,867		(27,853)
Cash generated by financing activities		4,986,668		250,932
Change in cash during the period		3,287,880		(80,027)
Cash, beginning of period		1,627,329		89,987
Cash, end of period	$	4,915,209	$	9,960

KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th

US lawmakers unlikely to prioritize banking reform

Cannabis rescheduling meets delays and controversies

Virginia makes progress on adult-use cannabis

Tilray sees growth across all segments in quarterly results

Latest News

Latest Press Releases

Related News

TOP STOCKS